3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008) [clinicaltrials:NCT00159744]

Bio2RDF identifier

NCT00159744

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00159744

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00159744

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

488

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00159744 arm group 04dd965d9687adfa910d4d33fc86f0c1 [clinicaltrials_resource:NCT00159744/arm-group/04dd965d9687adfa910d4d33fc86f0c1]

NCT00159744 arm group 0a6e71b1034abcd1f2d32e915b9fecee [clinicaltrials_resource:NCT00159744/arm-group/0a6e71b1034abcd1f2d32e915b9fecee]

NCT00159744 arm group 3f237303121a9d19106f8a7fd915e494 [clinicaltrials_resource:NCT00159744/arm-group/3f237303121a9d19106f8a7fd915e494]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

Bipolar disorder is cha ...... to 49 (study A7501007) weeks.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:e273f0481cfd1aad74b982b913939389]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:150661688c11e036905a936ee0e8a291]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:5ea403654645cad4626d041eddef4d29]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:5f116ff72a2f706ce22f23f16bfb1369]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:6d493d8fce2fbd625fda29b144af6839]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:7ef0ee8aec2a047a62e932541ca0ded4]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:88de6c50e45acecbe8d4261300df334d]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:909f7bf478fbb3aebbefa59dd5660888]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:c38da73cba4734509b2b3d081a8b9961]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:ccf517ed47ee7aad696a3ae07927a5a0]

Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) The YMRS was administered at screening, baseline, Day 2, 4, 7, 14 and 21 [clinicaltrials_resource:cd9387b36304fd0c234f62ea84024235]

collaborator [clinicaltrials_vocabulary:collaborator]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

completion date [clinicaltrials_vocabulary:completion-date]

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00159744 [clinicaltrials_resource:33f317fb502397d59806700014e1645f]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Placebo [clinicaltrials_resource:5e0582851341ba702f6103f0e032444b]

Olanzapine [clinicaltrials_resource:7989bf31009c8843bfd0af1b235d9df1]

Asenapine [clinicaltrials_resource:7ecf77f8b98a38234bdd0dd8493f8d6c]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Olanzapine [clinicaltrials_resource:394044b3109fa091d34a85a6ff71e1dd]

Asenapine [clinicaltrials_resource:3e380e274490b075ffc1291070fe33e4]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00159744

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

3

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase III, Randomized, Place ...... 501004 (Secondary Title: ARES)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

P07008

http://www.w3.org/2001/XMLSchema#string

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

A7501004

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

start date [clinicaltrials_vocabulary:start-date]

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00159744 study design [clinicaltrials_resource:7bbbdebee1b4c676ab624e35124438d0]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00159744

verification date [clinicaltrials_vocabulary:verification-date]

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00159744

http://www.w3.org/2001/XMLSchema#string

title

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

3-Week Study of Asenapine, Ola ...... ) [clinicaltrials:NCT00159744]

@en